What IBS actually is and how the classification has shifted
IBS is formally defined as a disorder of gut-brain interaction. That term replaced the older classification of functional gastrointestinal disorder in recent years, a change that reflects a growing understanding that IBS involves real, measurable physiological changes rather than simply being symptoms without a structural cause.
The disorder of gut-brain interaction framing captures the bidirectional nature of IBS well. The gut sends aberrant signals to the brain. The brain interprets them as pain and threat. The stress response that follows affects gut motility and sensitivity. The gut becomes more reactive. The brain becomes more vigilant. The cycle is self-sustaining.
What this framing does not fully capture is the structural component that research has increasingly been identifying. More than 25 studies have now assessed intestinal permeability in people with IBS using in-vivo testing methods. The consistent finding across these studies is that a significant proportion of IBS patients show measurably increased intestinal permeability compared to healthy controls. The gut lining is not merely a bystander in IBS. In many people it is a primary driver of the symptoms.
A 2025 review in Gastroenterology confirmed that more than 25 studies have assessed in-vivo intestinal permeability in IBS patients, finding low-grade immune activation in IBS and functional dyspepsia, with infiltration and activation of mast cells and eosinophils, and mast cells localised close to mucosal nerve endings in ways that suggest a direct role in symptom generation. View source →
The four IBS subtypes and why they matter for understanding your symptoms
IBS is not a single condition. It is a collection of symptom patterns that share common mechanisms but differ in how they present. Understanding which subtype applies to you matters because the gut lining and immune involvement differs across subtypes, and the approaches that help differ accordingly.
The gut lining's role in IBS: what the research now confirms
The intestinal epithelium in IBS shows specific structural abnormalities that distinguish it from healthy tissue. These are not subtle statistical differences visible only in large populations. They are measurable changes in the proteins that hold the gut lining together, the cells that produce the mucus layer, and the immune populations that reside within the gut wall.
The tight junctions between intestinal cells are held together by specific proteins, primarily claudin, occludin, and zonula occludens. In IBS-D, studies have consistently found reduced expression of claudin-1 and occludin in intestinal biopsy tissue compared to healthy controls. These are the specific structural components that maintain the gut barrier. Their reduction directly explains the increased permeability measured in IBS patients: the molecular components of the barrier are deficient.
This is not a chicken and egg question. The protein deficits are present in IBS tissue independent of the severity of current symptoms, suggesting they are a structural feature of the condition rather than simply a consequence of a current flare. The barrier is structurally compromised at the molecular level in a measurable, consistent way.
The mucus layer that coats the intestinal epithelium is the first line of defence between the gut wall and its contents. In IBS, research has found measurable abnormalities in the composition and thickness of this mucus layer, with altered mucin glycoprotein profiles and reduced protective function. A thinner or compositionally abnormal mucus layer means that bacteria, food antigens, and irritants have more direct access to the epithelial cells beneath.
This mucus layer abnormality is particularly relevant in IBS-D, where the faster transit time through the colon also reduces the contact time available for the mucus layer to form adequately. The result is a double vulnerability: structurally compromised tight junctions and a thinner mucus layer above them providing less protection.
The cells of the intestinal lining are fuelled primarily by butyrate, a short-chain fatty acid produced by the gut microbiome from dietary fibre fermentation. In IBS, microbiome dysbiosis consistently reduces the populations of butyrate-producing bacteria. This creates an energy deficit at the cellular level: the cells that maintain the gut lining are receiving less of the fuel they need to function and renew properly.
A 2025 study published in Gut Microbes used a novel colonoscopy model to assess the acute effects of butyrate on intestinal permeability in IBS patients directly. The finding was that butyrate acutely reduced intestinal permeability in IBS tissue, confirming that the butyrate deficit in IBS is functionally significant for barrier integrity and not merely a correlational observation.
"A 2025 study confirmed that butyrate acutely reduced intestinal permeability in IBS tissue. The gut lining in IBS is not merely irritated. It is structurally under-fuelled."
Mast cells, immune activation and the pain connection
One of the most significant developments in IBS research over the last decade is the identification of immune activation within the gut wall as a central mechanism in symptom generation. This does not mean IBS is an inflammatory condition in the way that Crohn's disease or ulcerative colitis is. The inflammation in IBS is low-grade and often below the threshold detectable in standard clinical testing. But it is measurable, consistent, and mechanistically important.
Mast cells are immune cells that reside within the gut wall. They release inflammatory mediators including histamine, tryptase, and prostaglandins in response to triggers including stress, certain foods, bacterial products crossing the gut barrier, and direct damage to the mucosal lining. Research has found that mast cells in IBS tissue are increased in number and are located closer to the mucosal nerve endings than in healthy tissue.
This proximity matters enormously for understanding IBS pain. When mast cells localised near nerve endings release histamine and tryptase, these mediators directly activate the sensory nerves in the gut wall. The nerve signals that reach the brain are interpreted as abdominal pain, urgency, and discomfort. The visceral hypersensitivity that is characteristic of IBS, the experience of pain at lower stimulus thresholds than normal, is substantially driven by this mast cell and nerve ending interaction within a compromised gut lining.
The 2025 Gastroenterology review confirmed that mast-cell targeted treatments have shown success in IBS, validating the mechanistic role of mast cell activation in symptom generation. The researchers noted that mast cells in both IBS and functional dyspepsia were "localised more closely to mucosal nerve endings, suggesting a role in symptom generation," and that the barrier defect and immune activation are likely bidirectionally reinforcing rather than one being purely causal. View source →
The microbiome dysbiosis that runs through every IBS subtype
Gut microbiome dysbiosis is one of the most consistently documented features of IBS across all subtypes. A 2025 narrative review in Frontiers in Immunology confirmed that dysbiosis of the gut microbiota is associated with IBS across the full range of the condition, and that the gut microbiota modulates IBS symptoms through multiple pathways: the epithelial barrier, mucosal immunity, microbial metabolites including short-chain fatty acids and bile acids, and gut-brain signalling.
What this means in practice is that the microbiome and the gut lining in IBS are caught in the same reinforcing cycle that we see in intestinal permeability more broadly. A compromised gut lining allows bacteria and bacterial products to cross into the gut wall tissue, triggering immune activation that further damages the lining. A dysbiotic microbiome produces less butyrate, reducing the fuel available to epithelial cells for maintaining the barrier. Each feeds the other.
Post-infectious IBS illustrates this cycle particularly clearly. A significant subset of IBS cases develop following a gastrointestinal infection. The infection damages the gut lining directly. The antibiotic treatment of the infection disrupts the microbiome. The combination of barrier damage and microbiome disruption creates the conditions for persistent IBS that continues long after the original infection has cleared.
What triggers and worsens gut lining disruption in IBS
Understanding the specific factors that compromise the gut lining in an IBS context is practically useful because it identifies what is worth avoiding or reducing, separately from dietary trigger management.
- Psychological stress is among the most potent triggers for IBS flares and also among the most potent disruptors of gut lining integrity. Cortisol reduces prostaglandin production, thins the mucosal layer, and activates mast cells in the gut wall. Every significant stressor has a direct physiological pathway into the gut lining, not as a metaphor but through documented neuroendocrine mechanisms.
- Certain dietary components can directly affect gut barrier function independently of whether they are identified as personal dietary triggers. Emulsifiers found in ultra-processed foods, particularly polysorbate-80 and carboxymethylcellulose, have been shown to alter the mucus layer and increase intestinal permeability. This is distinct from and additional to the more commonly discussed fermentable carbohydrate effects on IBS symptoms.
- Disrupted sleep impairs gut barrier function through its effects on the circadian rhythms that govern tight junction protein expression and mucosal immune function. Sleep disruption and IBS severity are bidirectionally correlated, with each worsening the other through overlapping mechanisms.
- NSAID use directly damages the mucosal layer and tight junction integrity, worsening the structural gut lining deficits already present in IBS. This is particularly significant because many people with IBS use ibuprofen or aspirin for the pain and headaches that often accompany the condition, inadvertently worsening its structural foundation.
- Gastrointestinal infections can shift IBS from a managed state to a significant relapse by directly damaging the gut lining and disrupting the microbiome simultaneously. Post-infectious IBS flares often represent a step-change in barrier function that requires active support to stabilise.
What commonly supports gut lining function in an IBS context
Given that gut lining integrity is a central physiological feature of IBS rather than a peripheral one, supporting the gut lining directly is a logical component of any comprehensive approach to managing the condition. The following approaches have the most consistent research support in an IBS context.
Given the 2025 research confirming that butyrate acutely reduces intestinal permeability in IBS tissue, supporting butyrate production through diet is one of the most mechanistically justified approaches available. Butyrate is produced by gut bacteria from fermentable fibre. Increasing the diversity and quantity of fibre in the diet, particularly from prebiotic sources including garlic, onions, leeks, asparagus, oats, and resistant starch, provides the substrate the microbiome needs to produce more butyrate.
This needs to be balanced with individual tolerance: some fermentable fibres that are excellent butyrate precursors are also high-FODMAP and may worsen bloating and pain in some IBS patients. Starting with small amounts and increasing gradually allows tolerance to be assessed individually.
L-Glutamine is the primary fuel source for intestinal epithelial cells and the most researched amino acid for gut barrier function. In an IBS context, where the cells of the gut lining are already operating in a structurally compromised environment, L-Glutamine provision at a clinically meaningful dose directly supports the energy available for tight junction maintenance and mucosal cell renewal.
Research has specifically examined L-Glutamine in IBS-D, finding that supplementation at a dose of 15g per day significantly reduced intestinal permeability and improved IBS symptom scores over an eight-week period. The results were most pronounced in patients who had developed IBS following a gastrointestinal infection, suggesting that the barrier repair mechanism is particularly relevant in this subgroup.
Because the gut lining and the microbiome are mutually dependent in IBS, supporting one without addressing the other is a partial approach. Probiotic supplementation in IBS has variable evidence depending on strain and subtype, but consistent findings support the value of Lactobacillus and Bifidobacterium strains for overall IBS symptom management, and specific spore-forming strains including Bacillus Coagulans for reducing bloating and improving digestive comfort.
Dietary diversity is ultimately the most powerful driver of microbiome recovery and maintenance. The research consistently associates greater dietary variety with greater microbial diversity, which in turn is associated with better barrier function, more butyrate production, and lower levels of intestinal inflammation. This is not a quick fix but it is a durable one.